What are the recommended medications for treating COVID‑19 based on disease severity and patient risk factors?

Medication for COVID-19

For non-severe COVID-19 in high-risk patients, use nirmatrelvir/ritonavir as first-line treatment within 5 days of symptom onset; for hospitalized patients requiring oxygen, use dexamethasone; and for severe/critical disease with inflammation, add tocilizumab or other IL-6 inhibitors to corticosteroids. 1

Risk Stratification First

Determine patient risk category immediately:

• High risk: Age ≥60 years, immunocompromised (including hematologic malignancies, transplant recipients), unvaccinated, multiple comorbidities (diabetes, obesity, chronic kidney disease, heart disease, COPD)
• Moderate risk: Age 50-59 with 1-2 comorbidities, vaccinated with some risk factors
• Low risk: Young, healthy, vaccinated, no significant comorbidities

Non-Severe COVID-19 (Outpatient or Mild Hospitalized)

High-Risk Patients

Nirmatrelvir/ritonavir (Paxlovid) is the superior choice - strong recommendation 1, 2:

• Start within 5 days of symptom onset
• High certainty evidence for reducing hospitalization and mortality
• Critical caveat: Extensive drug-drug interactions via ritonavir's CYP3A4 inhibition - check all medications, especially tacrolimus (reduce dose by 1/20-1/50), statins, and anticoagulants 3
• Safe in pregnancy and breastfeeding despite theoretical concerns 1

If nirmatrelvir/ritonavir contraindicated or unavailable:

1. Remdesivir (3-day IV course) - conditional recommendation 1

   • Requires IV access, limiting outpatient feasibility
   • Stable activity across variants

2. Molnupiravir - conditional recommendation, but inferior to above 1, 2

   • Use only when better options unavailable
   • Safety concern: Potential mutagenic effects and theoretical carcinogenicity from preclinical data
   • Moderate certainty for reducing hospitalization but smaller effect than nirmatrelvir/ritonavir

Moderate-Risk Patients

Suggest nirmatrelvir/ritonavir - conditional recommendation 1

• Benefit smaller than high-risk group but still meaningful
• Same drug interaction precautions apply

Low-Risk Patients

Do NOT use antivirals - conditional recommendation against 1

• Trivial benefit with high certainty evidence
• Reserve limited resources for higher-risk patients

Special Populations

Hematologic malignancy/transplant patients 4:

• Anti-SARS-CoV-2 monoclonal antibodies for post-exposure prophylaxis (high-risk, unvaccinated, or vaccine non-responders)
• Same antiviral hierarchy applies but with lower threshold for treatment
• Consider convalescent plasma if monoclonal antibodies unavailable (within 72 hours of symptom onset)

Moderate COVID-19 (Hospitalized, Requiring Oxygen, SpO2 >90%)

Combination therapy approach 4, 5:

1. Remdesivir - 5-day course 4, 6, 5
2. Dexamethasone 6 mg daily for 10 days - strong recommendation 4, 7, 5, 8, 9
   • Moderate certainty evidence for mortality benefit
   • Only use if requiring supplemental oxygen
3. If seronegative: Add casirivimab/imdevimab or convalescent plasma 4

Severe/Critical COVID-19 (SpO2 <90%, RR >30, or Mechanical Ventilation)

Layered immunomodulation strategy 4, 5:

Foundation Therapy

• Dexamethasone 6 mg daily - strong recommendation, moderate certainty 5, 8, 9
  • Proven mortality reduction in RECOVERY trial (41.4% vs 29.3% in ventilated patients)
  • Do NOT use in non-hypoxemic patients (strong recommendation against) 5

Add Second Immunosuppressant if Worsening Despite Dexamethasone

IL-6 receptor antagonists - conditional recommendation 4, 5:

• Tocilizumab or sarilumab (preferred)
• Only if COVID-19-related inflammation present (elevated inflammatory markers)
• Low certainty evidence but meaningful mortality benefit when combined with corticosteroids

Alternative immunomodulators 4:

• Anakinra (anti-IL-1)
• Baricitinib/tofacitinib (JAK inhibitors) - baricitinib specifically studied with remdesivir 6, 8

Antiviral Considerations in Severe Disease

• Remdesivir: Conditional recommendation 4, 5
• Casirivimab/imdevimab: Only if seronegative and on non-invasive ventilation (no data for invasive ventilation) 4

Critical Pitfalls to Avoid

1. Timing is everything: Antivirals ineffective if started >5-7 days after symptom onset 1, 10
2. Never use dexamethasone in non-hypoxemic patients - increases harm 5
3. Do NOT use (strong recommendations against):
   • Hydroxychloroquine ± azithromycin 6, 3, 5
   • Lopinavir/ritonavir 3, 5
   • Ivermectin 6, 2
   • Colchicine in hospitalized patients 5
4. Thromboprophylaxis mandatory for all hospitalized patients - strong recommendation despite very low evidence quality 5, 9
5. Drug interactions with nirmatrelvir/ritonavir require dose adjustments for immunosuppressants, anticoagulants, statins, and many other medications 3, 1

Respiratory Support

For hypoxemic respiratory failure without immediate intubation indication 5:

• High-flow nasal cannula (HFNC) or non-invasive CPAP (helmet or facemask)
• Consider awake prone positioning 7

What NOT to Do

The evidence is clear these have no role:

• Convalescent plasma (insufficient data outside trials) 6
• Interferon-β 5
• Inhaled corticosteroids for routine community treatment 10
• Systemic corticosteroids without hypoxemia 5, 9